$RARE has a robust portfolio consisting of 5 FDA-approved rare disease therapies, headlined by its recently greenlit gene therapy GENGLYCOS™. Its expanding commercial footprint supports a high-value clinical pipeline that's fast approaching critical late-stage inflection points.
$RARE Catalyst: GENGLYCOS™ Commercial Rollout: Near-term commercial launch in the U.S. within 30 to 60 days at a wholesale acquisition price of $2.7 million per patient.
$RARE Catalyst: September 19, 2026 – UX111 PDUFA Date: The FDA's priority review action deadline to rule on the approval of the UX111 gene therapy for Sanfilippo syndrome Type A.
$RARE: The PRV unlocked by the Genglycos approval is a massive non-dilutive financing event. Pocketing ~$200 million in pure cash from a voucher sale allows them to fund their clinical pipeline and execute their upcoming commercial launches without needing to issue new equity.
BREAKING: Iran rejects US Treasury Sec. Bessent's and Trump's claim that the Strait of Hormuz will open tomorrow under a new deal, saying Iran-Oman Hormuz negotiations, held without US participation, are instead aimed at establishing an "intermediate corridor" that will halt both the current Iran-controlled northern and US-backed southern routes, giving Iran as a coastal state fully protected sovereignty, interests, and national security, an informed source tells Press TV.
Iran adds "Trump has violated his commitments, and Iran is moving forward with its plan to establish arrangements in the Strait independently of US threats, and it will succeed," saying "Iran does not shape its interests and priorities based on schedule or demands of Trump."
The agreement with Oman would grant Iran total sovereign authority over all inbound maritime traffic, with Oman's limited role being to clear outbound vessels but only after notifying Iranian officials, ensuring Iran retains visibility and the option to intervene.
$ABVX “We are currently assessing how much money we need to raise in, let’s say, late June… to take us to profitability.” Funds raised would be at least several million, he added.
https://t.co/yXQZm4rfIF
🟢 DIRECTOR BUY — $OTLK
Hilzinger Kurt J buys $177K
• 400,000 shares @ $0.44
• New/major position
• Stock −87% from 52W high
• Trade: May 26, 2026 | Filed: May 27, 2026
💡 Strong Signal
#InsiderTrading#OTLK
$OTLK Before receiving the Complete Response Letter (CRL) from the FDA on December 31, 2025, Outlook Therapeutics (NASDAQ: OTLK) stock was trading between $1.80 and $2.47 per share throughout December. https://t.co/vAZlvcs9tW